Key result
Sarcopenic obesity is linked to ~130% higher risk of cardiometabolic multimorbidity.
Why the study?
Is sarcopenic obesity associated with an increased risk of cardiometabolic multimorbidity in middle-aged and older adults?
Observational (n=15,252)
Is sarcopenic obesity associated with an increased risk of cardiometabolic multimorbidity in middle-aged and older adults?
Answers are grounded in this paper and cite their sources.
Sarcopenic obesity is independently associated with a significantly higher risk of developing cardiometabolic multimorbidity in middle-aged and older adults compared to sarcopenia or obesity alone.
OBJECTIVES: Sarcopenic obesity (SO) has been found to increase the risk of metabolic disorders, however, its relationship with cardiometabolic multimorbidity (CMM) remains unexplored. This study aims to investigate the potential association between SO and CMM in the middle-aged and older population. METHODS: ). CMM was defined as having two or more cardiometabolic diseases, including diabetes mellitus, stroke, and heart disease. The participants were divided into four groups according to their sarcopenia and obesity status, and logistic regression analysis was used to examine the association between SO and CMM. RESULTS: A total of 15,252 study subjects were included in the cross-sectional study, with an average age of 60.6 years and a male proportion of 47.4%. In the cross-sectional analysis conducted in 2015, the prevalence of CMM was highest in the SO group (9.1%), followed by the obesity (3.7%) and sarcopenia (3.5%) group. After adjustment for confounding factors, SO [OR (95%CI): 2.453 (1.742-3.455)], sarcopenia [OR (95% CI): 1.601 (1.157-2.217)], obesity [OR (95% CI): 1.446 (1.107-1.888)] were all observed to be associated with CMM, with the strongest association in the SO group. Furthermore, in the longitudinal analysis, only the SO group demonstrated a significant risk for developing CMM [OR (95% CI): 2.302 (1.239-4.228)]. CONCLUSIONS: SO was independently and positively associated with CMM in middle-aged and older population.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2024) conducted an observational in Cardiometabolic multimorbidity (n=15,252). Sarcopenic obesity vs. No sarcopenic obesity was evaluated on Cardiometabolic multimorbidity (CMM) (OR 2.453, 95% CI 1.742-3.455). Sarcopenic obesity was significantly associated with cardiometabolic multimorbidity in cross-sectional (OR 2.453; 95% CI 1.742-3.455) and longitudinal analyses (OR 2.302; 95% CI 1.239-4.228).
Synapse has enriched 10 related papers. Consider them for comparative context: